 U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Jan. 9, 2023 PRNewswire Alterity Therapeutics ASX: ATH, NASDAQ: ATHE Alterity or the Company, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Companys Phase 2 clinical trial of ATH434 for the treatment of patients ...... 